1[3]Greenfield LJ, McCurdy JR, Brown PP, et al. A new intracaval filter permitting continued flow and resolution of embolision[J]. Surgery, 1973, 73 : 599 - 606
2王凤山，中国生物药物杂志，1998年，19卷，4期，197页
3周希静，肾脏病学，1995年，494页
4陈恩宏，中华肾脏病杂志，1988年，4卷，4期，3页
5董德长，中华内科杂志，1982年，21卷，2期，99页
6Hirsh J.In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding[].Haemostasis.1986
7Verhaeghe R.The use of low-molecular-weight heparins in cardiovascular disease[].Acta Cardiologica.1998
4Fareed j,Hoppensteadt DA.Pharmacology of the low-molecularweight hepadnsr[J].Semin Thromb Hemost,1996,22(Suppl 2):13-18.
5Jonas S,Sugimori M,Llinas R.Is low molecular weight hcparin aneuroprotectant[J]. Ann N Y Acad Sci,1997,825:389-393.
6Baram D,Rashkovsky M,Hershkoviz R,et al.Inhibitory effects of low molecular weight heparin on mediator release by mast cell:preferential inhibition of cytokine production and mast cell-dependent-cutaneous inflammation[J].Clin Exp lmmunol,1997,110(3):485-491.
